A phase III protocol of androgen suppression (AS) and radiation therapy (RT) vs AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide for localized, high-risk, prostate cancer

Trial Profile

A phase III protocol of androgen suppression (AS) and radiation therapy (RT) vs AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide for localized, high-risk, prostate cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Estramustine (Primary) ; Etoposide (Primary) ; Paclitaxel (Primary) ; Antiandrogens; Antineoplastics; Bicalutamide; Flutamide; Gonadotropin releasing hormone stimulants; Goserelin; Leuprorelin; LHRH receptor agonists
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results of a secondary analysis by post-radiation PSA status to identify patients that benefit from treatment intensification (n=333), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 13 Nov 2013 New source identified and integrated (M.D. Anderson Cancer Center, RTOG99-02).
    • 08 Jun 2010 Efficacy results have been presented at ASCO 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top